

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.


Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS


IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

A)



B)



VH primers:

a	DP47baNco	GCG GCC CAG CAT GCC ATG GCC GAG GTG CAG CTG TTG GAG TCT GGG
b	CDR3for	GGT TCC CTG GCC CCA GTA GTC AAA MNN MNN MNN MNN TTT CGC ACA GTA ATA TAC G
c	VHpulth	GCG GCC CAG CAT GCC ATG GCC GAG
d	Jassm	CCC GCT ACC GCC ACT GGA CCC ATC GCC ACT CGA GAC GGT GAC CAG GGT TCC CTG GCC CCA GTA GTC

VL primers:

e	DPK22assm	GAT GGG TCC AGT GGC GGT AGC GGG GGC GCG TCG ACT GGC GAA ATT GTG TTG ACG CAG TCT CC
f	DPK3for	CAC CTT GGT CCC TTG GCC GAA CGT MNN CGG MNN MNN ACC MNN CTG CTG ACA GTA ATA CAC TGC
g	Jfornot	GAG TCA TTC TCG ACT TGC GGC CGC TTT GAT TTC CAC CTT GGT CCC TTG GCC GAA CG
h	pulth	GAT GGG TCC AGT GGC GGT AGC GGG

Figure 1




Figure 2A




Figure 2B



Figure 3





Figure 4



time (h) \ %ID/g	scFv (L19)							scFv (D1.3)	
	Kidney	Spleen	Lung	Liver	Brain	Blood	Tumor	Blood	Tumor
0.25	26.4 ± 4.7	5.4 ± 0.4	15.1 ± 5.1	5.7 ± 0.6	0.4 ± 0.04	14.4 ± 2.6	4.6 ± 1.0	12.7 ± 0.1	4.4 ± 0.4
1	19.2 ± 3.9	3.8 ± 0.3	9.8 ± 0.9	2.8 ± 0.3	0.3 ± 0.1	8.3 ± 0.9	6.9 ± 2.4	5.7 ± 0.7	3.6 ± 1.0
3	8.1 ± 1.6	2.0 ± 0.3	5.0 ± 1.4	1.7 ± 0.02	0.2 ± 0.01	4.3 ± 0.3	8.2 ± 4.2	—	—
5	4.2 ± 1.1	1.8 ± 0.2	3.5 ± 0.2	1.3 ± 0.3	0.1 ± 0.02	2.0 ± 1.6	7.7 ± 2.5	4.6 ± 1.2	2.6 ± 1.5
24	0.7 ± 0.1	0.4 ± 0.1	1.0 ± 0.1	0.2 ± 0.04	0.02 ± 0.01	0.4 ± 0.1	4.7 ± 0.6	1.1 ± 0.5	0.7 ± 0.4

Figure 5

VH

E V Q L L E S G G G	L V Q P G G S L R L	S C A A S G F T F S
S F S M S W V R Q A	P G K G L E W V S S	I S G S S G T T Y Y
A D S V K G R F T I	S R D N S K N T L Y	L Q M N S L R A E D
T A V Y Y C A K P F	P Y F D Y W G Q G T	L V T V S S


linker

G D G S S G G S G G A S T G

VL

E I V L T Q S P G T	L S L S P G E R A T	L S C R A S Q S V S
S S Y L A W Y Q Q K	P G Q A P R L L I Y	Y A S S R A T G I P
D R F S G S G S G T	D F T L T I S R L E	P E D F A V Y Y C Q
Q T G R I P P T F G	Q G T K V E I K	

Figure 6: Amino acid sequence of antibody L19



day 9 / rabbit 1 / left / nC



day 9 / rabbit 1 / right / VEGF high



day 9 / rabbit 2 / left / PMA



day 9 / rabbit 2 / left / VEGF low



day 9 / rabbit 3 / left / VEGF high



day 9 / rabbit 3 / right / PMA



day 9 / rabbit 4 / left / PMA



day 9 / rabbit 4 / right / nC

Figure 7




Figure 8





FIG. 9




FIG. 10




FIG. 11




FIG. 12

FIGURE 13





FIGURE 14





FIGURE 15

Radioimmunotherapy with anti-angiogenesis antibodies



vessels = 0.5 - 5%
of total tumour mass





FIGURE 16





FIGURE 17a

^1H -NMR spectrum of 3-(trimethylstannyl)-benzoic acid in CDCl_3



$(\text{CH}_3)_3$

```

Current Data Parameters
NAME      test_0004
EXPNO     1
PROCNO    1

F2 - Acquisition Parameters
Date_     990804
Time      11.19
INSTRUM   drx600
PROBHD    5 mm TXI 13C
PULPROG   zgpg. eth
TO        8192
SOLVENT   CDCl3
NS        16
DS        2
SWH        9615.385 Hz
FIDRES     1.173753 Hz
AQ         0.4260340 sec
RG         800
DH         52.000 usec
DE         8.00 usec
TE         294.0 K
D1         1.00000000 sec

***** CHANNEL f1 *****
NUC1       1H
P1         8.00 usec
PL1        0.00 dB
PL9        120.00 dB
SFO1       600.1328114 MHz

***** GRADIENT CHANNEL *****
GPMAN1     sine.32
GPX1       0.00 x
GPY1       0.00 x
GPZ1       50.00 x
PZ1        1000.00 usec

F2 - Processing parameters
SI         4096
SF         600.1300239 MHz
MDK        65196
SSB        3
LB         0.00 Hz
GB         0
PC         1.00

1D NMR plot parameters
CX         20.00 cm
F1P        8.811 ppm
F1         5287.97 Hz
F2P        -0.341 ppm
F2         -204.88 Hz
PPMCH      0.45764 ppm/cm
  
```






FIGURE 17b

^1H -NMR spectrum of 3-(trimethylstannyl)-benzoic acid in CDCl_3



Current Data Parameters
NAME test_0004
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date_ 990804
Time 11.19
INSTRUM drx600
PROBHD 5 mm TXI 13C
PULPROG zgpg. eth
TD 8192
SOLVENT CDCl3
NS 16
DS 2
SWH 9615.385 Hz
FIDRES 1.173753 Hz
AQ 0.4260340 sec
RG 800
DM 52.000 usec
DE 8.00 usec
TE 294.0 K
D1 1.00000000 sec

----- CHANNEL f1 -----
NUC1 ^1H
P1 8.00 usec
PL1 0.00 dB
PL9 120.00 dB
SFO1 600.1326114 MHz


----- GRADIENT CHANNEL -----
GPMAN1 sine.32
GPX1 0.00 %
GPY1 0.00 %
GPZ1 50.00 %
PZ1 1000.00 usec

F2 - Processing parameters
SI 4096
SF 600.1300239 MHz
WDW OSINE
SSB 3
LB 0.00 Hz
GB 0
PC 1.00

1D NMR plot parameters
CX 20.00 cm
FIP 8.513 ppm
F1 5108.78 Hz
F2 6.977 ppm
F2 4187.17 Hz
PPHCH 0.07678 ppm/cm

FIGURE 18a

^1H -NMR spectrum of N-succinimidyl-3-(trimethylstannyl)-benzoate in CDCl_3



m-MeATE

$(\text{CH}_3)_3$

$\text{CO}-\text{CH}_2-\text{CH}_2-\text{CO}$

C_6
 C_4
 C_5
 CHCl_3

4

9

9

8

7

6

5

4

3

2

1

ppm

FIGURE 18b

^1H -NMR spectrum of N-succinimidy-3-(trimethylstannyl)-benzoate in CDCl_3




FIGURE 19

EI-MS of N-succinimidy1-3-(trimethylstannyl)-benzoate in CDCl₃

